Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Remarks:
- Supporting study to exclude teratogenic effects, specifically related to levocardia, in rat offspring following exposure to synthetic esters
- Adequacy of study:
- supporting study
- Study period:
- 1990
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Remarks:
- acceptable restrictions include nonstandard dermal exposure, only a single dose group (2000 mg/kg/day), and administration on gestation days 0-19
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 990
- Report date:
- 1990
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- nonstandard dermal exposure, only a single dose (2000 mg/kg/day) in addition to sham controls, exposure on day 0-19 of gestation, limited details on exposure
- GLP compliance:
- no
- Limit test:
- no
Test material
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS:
Number of female Sprague-Dawley rats: 170
Number of male Sprague-Dawley rats: 50
Age at study initiation: approx. 9 weeks
Source: Charles River Laboratories, Portage, MI
Acclimation period: 2 weeks
Diet: Purina Certified Rodent Chow #5002 (meal), ad libitum
Water: tap water, ad libitum
ENVIRONMENTAL CONDITIONS:
Temperture (degrees Celsius): air-conditioned rooms set to 20-22 C
Relative humidity: 40-60%
Photoperiod (hrs dark/ hrs light): 12/12
Administration / exposure
- Route of administration:
- dermal
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST SITE
- Type of wrap if used: open exposure, no wrap
- Time intervals for shavings or clippings: animals were clipped/collared on gestation day 0, clipped once weekly thereafter, collars were replaced as necessary
- Exposure adminstered on clipped, intact skin
- Site: Dorsal
- Controls: The rats of the control group were clipped and collared as treated animals. The intact dorsal skin of each rat was stroked with the tip of a syringe, but no test material was applied - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused, M/F ratio per cage: 1/1
- Proof of pregnancy: vaginal plug/ sperm in vaginal smear referred to a day 0 of pregnancy - Duration of treatment / exposure:
- gestation days 0-19
- Frequency of treatment:
- daily
- Duration of test:
- Animals were sacrificed on day 20 of gestation
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Sham Control
- Dose / conc.:
- 2 000 mg/kg bw/day (nominal)
- Remarks:
- Stock 103
- Dose / conc.:
- 2 000 mg/kg bw/day (nominal)
- Remarks:
- Stock 461 (Negative Control)
- No. of animals per sex per dose:
- 25 presumed-pregnant females
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: Doses for Stock 103 were based on results of a 13-week dermal study prreviously conducted with the same material (Study #61923), Stock 461 was selected as the negative control based on the fact thaat it is also a base stock that has been demonstrated to be non-teratogenic in a previously conducted developmental toxicity study (# 40922)
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
Time schedule: At least once daily
Cage side observations checked: signs of pathosis, abortion, premature delivery, and death
DETAILED CLINICAL OBSERVATIONS: no data
BODY WEIGHT: yes
Time schedule: days 0, 6, 10, 16, and 20 of gestation
FOOD CONSUMPTION AND COMPOUND INTAKE: no
WATER CONSUMPTION AND COMPOUND INTAKE: no
POST-MORTEM EXAMINATIONS: yes
Sacrifice: On day 20 of gestation
Examination: Thoracic and abdominal cavities were exposed and the reproductive organs were examined grossly for evidence of pathosis - Ovaries and uterine content:
- Ovaries and uterine content were examined after sacrifice: yes
Examinations included:
- Gravid uterus weight: yes
- Number of corpora lutea per ovary of each pregnant female: yes
- Number and location of implantations: Yes
- Early resorptions: Yes
- Late resorptions: Yes
- Live and dead fetuses: Yes
- Other: ovaries of nonpregnant females were grossly examined and then discarded - Fetal examinations:
- - External examinations: yes - all per litter
- Visceral anomalies: yes - all per litter
- Skeletal examinations: No
- Head examinations: No - Statistics:
- - Analyses of variances and group comparison of maternal biophase, caesarean section, and fetal data were conducted using Fisher's Exact or Dunnett's test
- ANOVA followed by group comparisons using Bartlett's Test was applied to evaluate fetal visceral data
- Differences between control and treated groups were considered statistically significant if the probability of the difference being due to chance was less than 5% (p<0.05)
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- - Non-treatment related effects (often observed in collared animals): red nasal exudate, chromodacryorrhea, red vaginal discharge (previously noted in control females at this study facility).
- Treatment-related effects: decreased amount of stool and perineal staining. Transient (gestation day 3-7) "hunched" posture, decreased amount of stool, and soft stool with subsequent perineal staining was observed in a single female. - Dermal irritation (if dermal study):
- effects observed, treatment-related
- Description (incidence and severity):
- - Non-treatment related effects (often observed in collared animals): neck lesions
- Treatment-related effects: skin irritation, including erythema, edema, flaking, and scabbing, skin stiffening and cracking (stock 461 exposed mice only), - Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Stock 103 and Stock 461-exposed groups gained significantly less weight compared to control animals. Mean carcass weight and overall net body weight gain were significantly reduced.
- Food consumption and compound intake (if feeding study):
- not examined
- Description (incidence and severity):
- food was provided to animals ad libitum
- Food efficiency:
- not examined
- Description (incidence and severity):
- food was provided to animals ad libitum
- Water consumption and compound intake (if drinking water study):
- not examined
- Description (incidence and severity):
- water was provided to animals ad libitum
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Only uterine weights were examined
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not examined
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not examined - Changes in number of pregnant:
- no effects observed
- Other effects:
- no effects observed
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- LOAEL
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- dermal irritation
- Remarks on result:
- other: skin irritation (erythema, flaking, scabbing)
- Remarks:
- skin irritation (erythema, flaking, scabbing)
- Dose descriptor:
- LOAEL
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- Dose descriptor:
- NOAEL
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- changes in number of pregnant
- changes in pregnancy duration
- dead fetuses
- early or late resorptions
- effects on pregnancy duration
- maternal abnormalities
- necropsy findings
- number of abortions
- pre and post implantation loss
- total litter losses by resorption
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): no effects observed - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Description (incidence and severity):
- Observations considered not to be treatment-related: One fetus in the control group and one fetus exposed to Stock 103 were born with microphthalmia (left eye only). One Stock 461-exposed fetus was edematous and had anophthalmia (left eye) and brachdactyly (bilateral hindpaws). A second fetus exposed to Stock 461 had a shortened and filamentous tail.
- Skeletal malformations:
- not examined
- Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- - One fetus (stock 103-treated) had moderate dilation of the renal pelvis
- One fetus (stock 461-treated) had a common truncus arteriosus (common aortic and pulmonary trunk)
- One fetus (stock 461-treated) had situs inversus of the heart, vessels, lungs, and stomach
- Anomalies observed at the time of visceral examination by sectioning included dilation of the lateral ventricles of the brain (control group only), anophthalmia (control group only), microphthalmia (control group only), dilation of the renal pelvis (stock 103-treated group only) - Other effects:
- no effects observed
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- external malformations
- visceral malformations
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Applicant's summary and conclusion
- Conclusions:
- Stock 103 and Stock 461 (negative control) were adminstered once daily using dermal application to presumed pregnant rats at dose levels of 0 and 2000 mg/kg/day. All animals were exposed omn gestation days 1-19 and sacrificed on day 20.
Both materials produced slight to moderate skin irritation at the dosing site. A decrease in net body weight gain was the only sign of maternal toxicity observed in exposed animals. No adverse effects were noted for any of the reproductive parameters evaluated. Fetal development, specifically heart development, was unaffected by Stock 103 and Stock 461 treatment.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.